297
Views
3
CrossRef citations to date
0
Altmetric
PUBERTY

Comparison of triptorelin acetate vs triptorelin pamoate in the treatment of Central precocious puberty (CPP): a retrospective study

, , , , ORCID Icon, & show all
Pages 338-340 | Received 28 Jul 2018, Accepted 11 Aug 2019, Published online: 23 Aug 2019

References

  • Lee PA. Central precocious puberty. An overview of diagnosis, treatment, and outcome. Endocrinol Metab Clin North Am. 1999;28:901–918.
  • Carel JC, Eugster EA, Rogol A, et al. Consensus statement on the use of gonadotropin-releasing hormone analogs in children. Pediatrics. 2009;123:e752–e762.
  • Iughetti L, Predieri B, Ferrari M, et al. Diagnosis of central precocious puberty: endocrine assessment. J Pediatr Endocrinol Metab. 2000;13:709–715.
  • Brito VN, Spinola-Castro AM, Kochi C, et al. Central precocious puberty: revisiting the diagnosis and therapeutic management. Arch Endocrinol Metab. 2016;60:163–172.
  • Bayley N, Pinneau SR. Tables for predicting adult height from skeletal age: revised for use with the Greulich-Pyle hand standards. J Pediatr. 1952;40:423–441.
  • de Vries L, Phillip M. Role of pelvic ultrasound in girls with precocious puberty. Horm Res Paediatr. 2011;75:148–152.
  • de Vries L, Horev G, Schwartz M, et al. Ultrasonographic and clinical parameters for early differentiation between precocious puberty and premature thelarche. Eur J Endocrinol. 2006;154:891–898.
  • Mul D, Hughes IA. The use of GnRH agonists in precocious puberty. Eur J Endocrinol. 2008;159:S3–S8.
  • Neubig RR. Mind your salts: when the inactive constituent isn’t. Mol Pharmacol. 2010;78:558–559.
  • Bowker MJ. 2008. A procedure for salt selection and optimization. In: Stahl PH, Wermuth CG, editors. Handbook of pharmaceutical salts: properties, selection, and use. Weinheim: Wiley-VCH; pp 161–189.
  • Magiakou MA, Manousaki D, Papadaki M, et al. The efficacy and safety of gonadotropin-releasing hormone analog treatment in childhood and adolescence: a single center, long-term follow-up study. J Clin Endocrinol Metab. 2010;95:109–117.
  • Poomthavorn P, Suphasit R, Mahachoklertwattana P. Adult height, body mass index and time of menarche of girls with idiopathic central precocious puberty after gonadotropin-releasing hormone analogue treatment. Gynecol Endocrinol. 2011;27:524–528.
  • Pasquino AM, Pucarelli I, Accardo F, et al. Long-term observation of 87 girls with idiopathic central precocious puberty treated with gonadotropin-releasing hormone analogs: impact on adult height, body mass index, bone mineral content, and reproductive function. J Clin Endocrinol Metab. 2008;93:190–195.
  • Ságodi L, Sólyom E, Lombay B, et al. Effect of treatment with gonadotropin releasing hormone analogues in girls with idiopathic central precocious puberty. Orv Hetil. 2012;153:418–424.
  • Pienkowski C, Tauber M. Gonadotropin-releasing hormone agonist treatment in sexual precocity. Endocr Dev. 2016;29:214–229.
  • Partsch CJ, Heger S, Sippell WG. Treatment of central precocious puberty: lessons from a 15 years prospective trial. German Decapeptyl Study Group. J Pediatr Endocrinol Metab. 2000;13:747–758.
  • Zenaty D, Blumberg J, Liyanage N, et al. A 6-month trial of the efficacy and safety of Triptorelin Pamoate (11.25 mg) every 3 months in children with precocious puberty: a retrospective comparison with Triptorelin Acetate. Horm Res Paediatr. 2016;86:188–195.
  • Yoon JW, Park HA, Lee J, et al. The influence of gonadotropin-releasing hormone agonists on anthropometric change in girls with central precocious puberty. Korean J Pediatr. 2017;60:395–402.
  • Park J, Hwang TH, Kim YD, et al. Longitudinal follow-up to near final height of auxological changes in girls with idiopathic central precocious puberty treated with gonadotropin-releasing hormone analog and grouped by pretreatment body mass index level. Ann Pediatr Endocrinol Metab. 2018;23:14–20.
  • Głab E, Barg E, Wikiera B, et al. Influence of GnRH analog therapy on body mass in central precocious puberty. Pediatr Endocrinol Diabetes Metab. 2009;15:7–11.
  • Zhao P, Sharir H, Kapur A, et al. Targeting of the orphan receptor GPR35 by pamoic acid: a potent activator of extracellular signal-regulated kinase and β-arrestin2 with antinociceptive activity. Mol Pharmacol. 2010;78:560–568.
  • Delle Monache S, Calgani A, Sanità P et al. Adipose-derived stem cells sustein prolonged angiogenesis through leptin secretion. Growth factors 2016;34:87–96.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.